The role of serum C-reactive protein in women with lower urinary tract symptoms

International Urogynecology Journal

Volumn 23, Issue 7, 2012, Pages 935-940

  Hsiao, Sheng Mou ^a   Lin, Ho Hsiung ^b   Kuo, Hann Chorng ^c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

C reactive protein; Lower urinary tract symptoms; Urodynamic studies

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; BLADDER DISEASE; BLADDER OVERSENSITIVITY; BODY MASS; CONTROLLED STUDY; FEMALE; FLOW RATE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; OVERACTIVE BLADDER; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINE INCONTINENCE; UROFLOWMETRY;

EID: 84865144195     PISSN: 09373462     EISSN: 14333023     Source Type: Journal    
DOI: 10.1007/s00192-012-1715-1     Document Type: Article

References (30)

1. Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5-26
2. Hung MJ, Ho ES, Shen PS et al (2006) Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis. J Urol 176:636-640 (Pubitemid 43927928)
3. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543-562
4. Tyagi P, Barclay D, Zamora R et al (2010) Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 42:629-635
5. Khasriya R, Khan S, Lunawat R et al (2010) The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with lower urinary tract symptoms without acute frequency and dysuria. J Urol 183:1843-1847
6. Cartwright R, Afshan I, Derpapas A, Vijaya G, Khullar V (2011) Novel biomarkers for overactive bladder. Nat Rev Urol 8:139-145
7. Antunes-Lopes T, Pinto R, Carvalho-Barros S et al (2011) Urinary levels of brain derived neurotrophic factor (BDNF) in women with overactive bladder (OAB) syndrome correlate with the severity of symptoms. Eur Urol Suppl 10:277-278
8. Liu HT, Tyagi P, Chancellor MB, Kuo HC (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106:1681-1685
9. Kushner I (1982) The phenomenon of the acute phase response. Ann N Y Acad Sci 389:39-48 (Pubitemid 12013176)
10. Chung SD, Liu HT, Lin H, Kuo HC (2011) Elevation of serum C-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn 30:417-420
11. Kupelian V, McVary KT, Barry MJ et al (2009) Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey. Urology 73:950-957
12. St Sauver JL, Sarma AV, Jacobson DJ et al (2009) Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol 169:1281-1290
13. Homma Y, Yoshida M, Seki N et al (2006) Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urology 68:318-323 (Pubitemid 44175525)
14. Nixon A, Colman S, Sabounjian L et al (2005) A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174:604-607 (Pubitemid 40981612)
15. Chung SD, Liao CH, Chen YC, Kuo HC (2011) Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. Neurourol Urodyn 30:1300-1304
16. Kuo HC (2005) Videourodynamic characteristics and lower urinary tract symptoms of female bladder outlet obstruction. Urology 66:1005-1009
17. Kuo YC, Kuo HC (2012) Potential factors that can be used to differentiate between interstitial cystitis/painful bladder syndrome and bladder oversensitivity in women. Int J Clin Pract 66:146-151. doi:10.1111/j.1742-1241. 2011.02767.x
18. Altman DG (1991) Relation between several variables. In: Altman DG (ed) Practical statistics for medical research. Chapman & Hall, London, pp 325-364
19. Chuang YC, Tyagi V, Liu RT, Chancellor MB, Tyagi P (2010) Urine and serum C-reactive protein levels as potential biomarkers of lower urinary tract symptoms. Urol Sci 21:132-136
20. Compérat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E (2006) Histologic features in the urinary bladder wall affected from neurogenic overactivity - a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 50:1058-1064 (Pubitemid 44486475)
21. Apostolidis A, Jacques TS, Freeman A et al (2008) Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 53:1245-1253
22. Jang J, Park EY, Seo SI, Hwang TK, Kim JC (2006) Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int 98:435-439
23. Dmitrieva N, McMahon SB (1996) Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 66:87-97 (Pubitemid 26247028)
24. Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813-1818 (Pubitemid 32291421)
25. Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511 (Pubitemid 36158056)
26. Wee CC, Mukamal KJ, Huang A, Davis RB, McCarthy EP, Mittleman MA (2008) Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity (Silver Spring) 16:875-880 (Pubitemid 351465646)
27. Hwang JJ, Li HY, Shieh GJ, Chien YF, Hua CH, Lin JW (2008) Illustrating the roles of C-reactive protein in the development of the metabolic syndrome in women - a cross-racial validation. Nutr Metab Cardiovasc Dis 18:671-677
28. Aronson D, Bartha P, Zinder O et al (2004) Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 28:674-679 (Pubitemid 38580975)
29. Khera A, McGuire DK, Murphy SA et al (2005) Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 46:464-469 (Pubitemid 41040287)
30. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349:462-466 (Pubitemid 27077826)